Candel's CAN-2409 Phase 3 meets primary endpoint (p=0.0155) in localized prostate cancer; ASCO presentation June 3

Candel Therapeutics, Inc.

Statistically significant improvement in DFS (p=0.0155) with 30% risk reduction (HR 0.7) for CAN-2409 plus radiotherapy vs placebo plus radiotherapy.
Secondary endpoints met: 80.4% pathological complete response at two-year biopsy vs 63.6% control (p=0.0015); higher PSA nadir <0.2 ng/ml (67.1% vs 58.6%, p=0.0164).
CAN-2409 well tolerated; treatment-related serious adverse events low (1.7% drug arm vs 2.2% control).
Company plans to submit Biologics License Application for CAN-2409 in Q4 2026.
Data to be presented at ASCO 2025 oral abstract session on June 3, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.